Biotech Values

[genisi]

This part was not in NVS’ own PR on the FTY720 advisory panel:

The panel later voted 21 to 3 against a question that asked if other drugs should be tried first, which means it backed the use of Gilenia as a first-line treatment for multiple sclerosis.

http://online.wsj.com/article/BT-CO-20100610-714300.html?mod=WSJ_World_MIDDLEHeadlinesEurope